MKI67 and neuroendocrine carcinoma: The Nordic NEC study showed that HG GEP-NEN with a Ki-67 < 55% had a lower response rate (RR) to platinum/etoposide compared to patients with Ki-67 > 55% (15 vs. 42%) [13].